This page has only limited features, please log in for full access.
In the article entitled “Sudden Cardiac Death, Haemodialysis, Hydroxychloroquine, and COVID-19” [Blood Purif 2021, DOI: 10.1159/000515010], the author’s name is misspelled. “Viroj Wiwanitkti” should read “Viroj Wiwanitkit.”
C. Ronco; Japan Society For Blood Purification In Critical Care (Jsbpcc); Chinese Society Of Blood Purification Administration (Csbpa); Japanese Society For Hemodiafiltration (Js-Hdf); International Society of Blood Purification (ISBP); Peter Stenvinkel; Mei Wang; Akihiro C. Yamashita; Shigeto Oda; Gerhard Lonnemann; Kenichi Matsuda; Stefano Chiaramonte; Nathan W. Levin; Giovambattista Capasso; W.H. Hörl; Kiyoshi Kurokawa; Andrew Davenport; Roger N. Greenwood; Achim Joerres; Michael Haase; Nevin M. Katz; Alexandre Mebazaa; Francesca Martino; Martin K. Kuhlmann; John A. Kellum; Hideki Kawanishi; William F. Keane; Norbert Lameire; Andrew Mooney; Patrick T. Murray; Federico Nalesso; K. Shivanand Nayak; Bruce A. Molitoris; Didier Payen; Miguel Perez Fontan; Beth Marie Piraino; Piotr Ponikowski; Giuseppe Remuzzi; Richard Amerling; Ciro Tetta; Allen R. Nissenson; Madhukar Misra; Victor Gura; Enrico Eugenio Verrina; Stefan H. Jacobson; Stefan D. Anker; Ian C. Baldwin; Mihai Gheorghiade; Massimo Antonelli; Sean M. Bagshaw; Fabio Barbarigo; W. Kline Bolton; Joanne M. Bargman; Joseph V. Bonventre; Edwina A. Brown; John Burkart; David Goldsmith; Jorgen Hegbrant; Stuart L. Goldstein; William L. Henrich; Eric A. Hoste; George L. Bakris; Stefano Bianchi; Jordi Bover; Shigehiko Uchino; Rinaldo Bellomo; P.K.G. Chandran; Lakhmir Chawla; Jorge Cerda; John Collins; Maria Rosa Costanzo; Angel M. de Francisco; Dick de Zeeuw; Oliver Devuyst; Mariano Feriani; Fredric Finkelstein; Salvatore Di Somma; Rosanna Coppo; Ricardo Correa-Rotter; Adrian A. Covic; Mario Cozzolino; Carlo Crepaldi; Franceso Galli; Enrico Fiaccadori; Stephan von Haehling; Daniel Schneditz; Janusz Witowski; Carmine Zoccali; Guido Garosi; Volker Wizemann; Storker Jorstad; Jean-Pierre Wauters; Piergiorgio Messa; Olof Heimburger; Peter A. McCullough; Raymond T. Krediet; H.H. Vincent; Richard A. Ward; Ken Farrington; Rajnish Mehrotra; Peter Kotanko; Francesco Locatelli; Zhi-Hong Liu; Patrick Honoré; Christian Verger; Piet M. Ter Wee; Antonio Santoro; Talat Alp Ikizler; Sergio Stefoni; Markus Ketteler; Guido Bertolini; Daugirdas J.T.; A.A. Al-Khader; London Gerard; Alan Maisel; J. Louis Vanherweghem; Vincenzo La Milia; Pasquale Piccinni; V. Marco Ranieri; Heleen M. Oudemans-Van Straaten; Vincenzo Panichi; John R. Prowle; Miguel C. Riella; Marie Schetz; Mark Okusa; Mauro Pittiruti; Mitch Rosner; Jean-Philippe Ryckelynck; Isaac Teitelbaum; Josep Teixido-Planas; Wim Van Biesen; Michael Rocco; Zaccaria Ricci; Bengt Rippe; Andrea Stopper; Dirk G. Struijk; Angela Y. Wang; David Warnock; Michael J Lysaght; Igor M. Sauer; Andrew Shaw; Stanley Shaldon; Mizpah Publishing Service; Druckerei Stückle. Erratum. Blood Purification 2021, 1 -1.
AMA StyleC. Ronco, Japan Society For Blood Purification In Critical Care (Jsbpcc), Chinese Society Of Blood Purification Administration (Csbpa), Japanese Society For Hemodiafiltration (Js-Hdf), International Society of Blood Purification (ISBP), Peter Stenvinkel, Mei Wang, Akihiro C. Yamashita, Shigeto Oda, Gerhard Lonnemann, Kenichi Matsuda, Stefano Chiaramonte, Nathan W. Levin, Giovambattista Capasso, W.H. Hörl, Kiyoshi Kurokawa, Andrew Davenport, Roger N. Greenwood, Achim Joerres, Michael Haase, Nevin M. Katz, Alexandre Mebazaa, Francesca Martino, Martin K. Kuhlmann, John A. Kellum, Hideki Kawanishi, William F. Keane, Norbert Lameire, Andrew Mooney, Patrick T. Murray, Federico Nalesso, K. Shivanand Nayak, Bruce A. Molitoris, Didier Payen, Miguel Perez Fontan, Beth Marie Piraino, Piotr Ponikowski, Giuseppe Remuzzi, Richard Amerling, Ciro Tetta, Allen R. Nissenson, Madhukar Misra, Victor Gura, Enrico Eugenio Verrina, Stefan H. Jacobson, Stefan D. Anker, Ian C. Baldwin, Mihai Gheorghiade, Massimo Antonelli, Sean M. Bagshaw, Fabio Barbarigo, W. Kline Bolton, Joanne M. Bargman, Joseph V. Bonventre, Edwina A. Brown, John Burkart, David Goldsmith, Jorgen Hegbrant, Stuart L. Goldstein, William L. Henrich, Eric A. Hoste, George L. Bakris, Stefano Bianchi, Jordi Bover, Shigehiko Uchino, Rinaldo Bellomo, P.K.G. Chandran, Lakhmir Chawla, Jorge Cerda, John Collins, Maria Rosa Costanzo, Angel M. de Francisco, Dick de Zeeuw, Oliver Devuyst, Mariano Feriani, Fredric Finkelstein, Salvatore Di Somma, Rosanna Coppo, Ricardo Correa-Rotter, Adrian A. Covic, Mario Cozzolino, Carlo Crepaldi, Franceso Galli, Enrico Fiaccadori, Stephan von Haehling, Daniel Schneditz, Janusz Witowski, Carmine Zoccali, Guido Garosi, Volker Wizemann, Storker Jorstad, Jean-Pierre Wauters, Piergiorgio Messa, Olof Heimburger, Peter A. McCullough, Raymond T. Krediet, H.H. Vincent, Richard A. Ward, Ken Farrington, Rajnish Mehrotra, Peter Kotanko, Francesco Locatelli, Zhi-Hong Liu, Patrick Honoré, Christian Verger, Piet M. Ter Wee, Antonio Santoro, Talat Alp Ikizler, Sergio Stefoni, Markus Ketteler, Guido Bertolini, Daugirdas J.T., A.A. Al-Khader, London Gerard, Alan Maisel, J. Louis Vanherweghem, Vincenzo La Milia, Pasquale Piccinni, V. Marco Ranieri, Heleen M. Oudemans-Van Straaten, Vincenzo Panichi, John R. Prowle, Miguel C. Riella, Marie Schetz, Mark Okusa, Mauro Pittiruti, Mitch Rosner, Jean-Philippe Ryckelynck, Isaac Teitelbaum, Josep Teixido-Planas, Wim Van Biesen, Michael Rocco, Zaccaria Ricci, Bengt Rippe, Andrea Stopper, Dirk G. Struijk, Angela Y. Wang, David Warnock, Michael J Lysaght, Igor M. Sauer, Andrew Shaw, Stanley Shaldon, Mizpah Publishing Service, Druckerei Stückle. Erratum. Blood Purification. 2021; ():1-1.
Chicago/Turabian StyleC. Ronco; Japan Society For Blood Purification In Critical Care (Jsbpcc); Chinese Society Of Blood Purification Administration (Csbpa); Japanese Society For Hemodiafiltration (Js-Hdf); International Society of Blood Purification (ISBP); Peter Stenvinkel; Mei Wang; Akihiro C. Yamashita; Shigeto Oda; Gerhard Lonnemann; Kenichi Matsuda; Stefano Chiaramonte; Nathan W. Levin; Giovambattista Capasso; W.H. Hörl; Kiyoshi Kurokawa; Andrew Davenport; Roger N. Greenwood; Achim Joerres; Michael Haase; Nevin M. Katz; Alexandre Mebazaa; Francesca Martino; Martin K. Kuhlmann; John A. Kellum; Hideki Kawanishi; William F. Keane; Norbert Lameire; Andrew Mooney; Patrick T. Murray; Federico Nalesso; K. Shivanand Nayak; Bruce A. Molitoris; Didier Payen; Miguel Perez Fontan; Beth Marie Piraino; Piotr Ponikowski; Giuseppe Remuzzi; Richard Amerling; Ciro Tetta; Allen R. Nissenson; Madhukar Misra; Victor Gura; Enrico Eugenio Verrina; Stefan H. Jacobson; Stefan D. Anker; Ian C. Baldwin; Mihai Gheorghiade; Massimo Antonelli; Sean M. Bagshaw; Fabio Barbarigo; W. Kline Bolton; Joanne M. Bargman; Joseph V. Bonventre; Edwina A. Brown; John Burkart; David Goldsmith; Jorgen Hegbrant; Stuart L. Goldstein; William L. Henrich; Eric A. Hoste; George L. Bakris; Stefano Bianchi; Jordi Bover; Shigehiko Uchino; Rinaldo Bellomo; P.K.G. Chandran; Lakhmir Chawla; Jorge Cerda; John Collins; Maria Rosa Costanzo; Angel M. de Francisco; Dick de Zeeuw; Oliver Devuyst; Mariano Feriani; Fredric Finkelstein; Salvatore Di Somma; Rosanna Coppo; Ricardo Correa-Rotter; Adrian A. Covic; Mario Cozzolino; Carlo Crepaldi; Franceso Galli; Enrico Fiaccadori; Stephan von Haehling; Daniel Schneditz; Janusz Witowski; Carmine Zoccali; Guido Garosi; Volker Wizemann; Storker Jorstad; Jean-Pierre Wauters; Piergiorgio Messa; Olof Heimburger; Peter A. McCullough; Raymond T. Krediet; H.H. Vincent; Richard A. Ward; Ken Farrington; Rajnish Mehrotra; Peter Kotanko; Francesco Locatelli; Zhi-Hong Liu; Patrick Honoré; Christian Verger; Piet M. Ter Wee; Antonio Santoro; Talat Alp Ikizler; Sergio Stefoni; Markus Ketteler; Guido Bertolini; Daugirdas J.T.; A.A. Al-Khader; London Gerard; Alan Maisel; J. Louis Vanherweghem; Vincenzo La Milia; Pasquale Piccinni; V. Marco Ranieri; Heleen M. Oudemans-Van Straaten; Vincenzo Panichi; John R. Prowle; Miguel C. Riella; Marie Schetz; Mark Okusa; Mauro Pittiruti; Mitch Rosner; Jean-Philippe Ryckelynck; Isaac Teitelbaum; Josep Teixido-Planas; Wim Van Biesen; Michael Rocco; Zaccaria Ricci; Bengt Rippe; Andrea Stopper; Dirk G. Struijk; Angela Y. Wang; David Warnock; Michael J Lysaght; Igor M. Sauer; Andrew Shaw; Stanley Shaldon; Mizpah Publishing Service; Druckerei Stückle. 2021. "Erratum." Blood Purification , no. : 1-1.
Management of COVID-19 infection is the trend topic in the scientific community and case identification is a key step to contain the pandemic. While pneumonia and acute respiratory distress syndrome represent the typical severe manifestations of the disease, atypical presentations pose significant diagnostic and therapeutic challenges for physicians, especially when diagnostic tests are repeatedly negative. Clinical picture of COVID-19 patients is often complicated by bacterial infections or thrombotic events. Here, we present and discuss a case report identified in our center as example of a challenging diagnosis and 2 uncommon complications: severe hyponatremia and acute kidney injury requiring renal replacement therapy, caused by parenchymal damage and with a possible direct involvement of the virus.
Matthias Arnaldo Cassia; Roberta Casazza; Pietro Napodano; Mario Cozzolino. COVID-19 Infection and Acute Kidney Injury: Cause or Complication? Blood Purification 2021, 1 -4.
AMA StyleMatthias Arnaldo Cassia, Roberta Casazza, Pietro Napodano, Mario Cozzolino. COVID-19 Infection and Acute Kidney Injury: Cause or Complication? Blood Purification. 2021; ():1-4.
Chicago/Turabian StyleMatthias Arnaldo Cassia; Roberta Casazza; Pietro Napodano; Mario Cozzolino. 2021. "COVID-19 Infection and Acute Kidney Injury: Cause or Complication?" Blood Purification , no. : 1-4.
In the article by Mitaka et al. entitled “Impact of Extended Duration of Polymyxin B-Immobilized Fiber Column Direct Hemoperfusion on Hemodynamics, Vasoactive Substance Requirement, and Pulmonary Oxygenation in Patients with Sepsis: An Observational Study” [Blood Purif, DOI: 10.1159/000515685], one author name is misspelled. “Makio Kusao” should read “Makio Kusaoi.”
C. Ronco; Japan Society For Blood Purification In Critical Care (Jsbpcc); Chinese Society Of Blood Purification Administration (Csbpa); Japanese Society For Hemodiafiltration (Js-Hdf); International Society of Blood Purification (ISBP); Peter Stenvinkel; Mei Wang; Akihiro C. Yamashita; Shigeto Oda; Gerhard Lonnemann; Kenichi Matsuda; Stefano Chiaramonte; Nathan W. Levin; Giovambattista Capasso; W.H. Hörl; Kiyoshi Kurokawa; Andrew Davenport; Roger N. Greenwood; Achim Joerres; Michael Haase; Nevin M. Katz; Alexandre Mebazaa; Francesca Martino; Martin K. Kuhlmann; John A. Kellum; Hideki Kawanishi; William F. Keane; Norbert Lameire; Andrew Mooney; Patrick T. Murray; Federico Nalesso; K. Shivanand Nayak; Bruce A. Molitoris; Didier Payen; Miguel Perez Fontan; Beth Marie Piraino; Piotr Ponikowski; Giuseppe Remuzzi; Richard Amerling; Ciro Tetta; Allen R. Nissenson; Madhukar Misra; Victor Gura; Enrico Eugenio Verrina; Stefan H. Jacobson; Stefan D. Anker; Ian C. Baldwin; Mihai Gheorghiade; Massimo Antonelli; Sean M. Bagshaw; Fabio Barbarigo; W. Kline Bolton; Joanne M. Bargman; Joseph V. Bonventre; Edwina A. Brown; John Burkart; David Goldsmith; Jorgen Hegbrant; Stuart L. Goldstein; William L. Henrich; Eric A. Hoste; George L. Bakris; Stefano Bianchi; Jordi Bover; Shigehiko Uchino; Rinaldo Bellomo; P.K.G. Chandran; Lakhmir Chawla; Jorge Cerda; John Collins; Maria Rosa Costanzo; Angel M. de Francisco; Dick de Zeeuw; Oliver Devuyst; Mariano Feriani; Fredric Finkelstein; Salvatore Di Somma; Rosanna Coppo; Ricardo Correa-Rotter; Adrian A. Covic; Mario Cozzolino; Carlo Crepaldi; Franceso Galli; Enrico Fiaccadori; Stephan von Haehling; Daniel Schneditz; Janusz Witowski; Carmine Zoccali; Guido Garosi; Volker Wizemann; Storker Jorstad; Jean-Pierre Wauters; Piergiorgio Messa; Olof Heimburger; Peter A. McCullough; Raymond T. Krediet; H.H. Vincent; Richard A. Ward; Ken Farrington; Rajnish Mehrotra; Peter Kotanko; Francesco Locatelli; Zhi-Hong Liu; Patrick Honoré; Christian Verger; Piet M. Ter Wee; Antonio Santoro; Talat Alp Ikizler; Sergio Stefoni; Markus Ketteler; Guido Bertolini; Daugirdas J.T.; A.A. Al-Khader; London Gerard; Alan Maisel; J. Louis Vanherweghem; Vincenzo La Milia; Pasquale Piccinni; V. Marco Ranieri; Heleen M. Oudemans-Van Straaten; Vincenzo Panichi; John R. Prowle; Miguel C. Riella; Marie Schetz; Mark Okusa; Mauro Pittiruti; Mitch Rosner; Jean-Philippe Ryckelynck; Isaac Teitelbaum; Josep Teixido-Planas; Wim Van Biesen; Michael Rocco; Zaccaria Ricci; Bengt Rippe; Andrea Stopper; Dirk G. Struijk; Angela Y. Wang; David Warnock; Michael J Lysaght; Igor M. Sauer; Andrew Shaw; Stanley Shaldon; Mizpah Publishing Service; Druckerei Stückle. Erratum. Blood Purification 2021, 1 -1.
AMA StyleC. Ronco, Japan Society For Blood Purification In Critical Care (Jsbpcc), Chinese Society Of Blood Purification Administration (Csbpa), Japanese Society For Hemodiafiltration (Js-Hdf), International Society of Blood Purification (ISBP), Peter Stenvinkel, Mei Wang, Akihiro C. Yamashita, Shigeto Oda, Gerhard Lonnemann, Kenichi Matsuda, Stefano Chiaramonte, Nathan W. Levin, Giovambattista Capasso, W.H. Hörl, Kiyoshi Kurokawa, Andrew Davenport, Roger N. Greenwood, Achim Joerres, Michael Haase, Nevin M. Katz, Alexandre Mebazaa, Francesca Martino, Martin K. Kuhlmann, John A. Kellum, Hideki Kawanishi, William F. Keane, Norbert Lameire, Andrew Mooney, Patrick T. Murray, Federico Nalesso, K. Shivanand Nayak, Bruce A. Molitoris, Didier Payen, Miguel Perez Fontan, Beth Marie Piraino, Piotr Ponikowski, Giuseppe Remuzzi, Richard Amerling, Ciro Tetta, Allen R. Nissenson, Madhukar Misra, Victor Gura, Enrico Eugenio Verrina, Stefan H. Jacobson, Stefan D. Anker, Ian C. Baldwin, Mihai Gheorghiade, Massimo Antonelli, Sean M. Bagshaw, Fabio Barbarigo, W. Kline Bolton, Joanne M. Bargman, Joseph V. Bonventre, Edwina A. Brown, John Burkart, David Goldsmith, Jorgen Hegbrant, Stuart L. Goldstein, William L. Henrich, Eric A. Hoste, George L. Bakris, Stefano Bianchi, Jordi Bover, Shigehiko Uchino, Rinaldo Bellomo, P.K.G. Chandran, Lakhmir Chawla, Jorge Cerda, John Collins, Maria Rosa Costanzo, Angel M. de Francisco, Dick de Zeeuw, Oliver Devuyst, Mariano Feriani, Fredric Finkelstein, Salvatore Di Somma, Rosanna Coppo, Ricardo Correa-Rotter, Adrian A. Covic, Mario Cozzolino, Carlo Crepaldi, Franceso Galli, Enrico Fiaccadori, Stephan von Haehling, Daniel Schneditz, Janusz Witowski, Carmine Zoccali, Guido Garosi, Volker Wizemann, Storker Jorstad, Jean-Pierre Wauters, Piergiorgio Messa, Olof Heimburger, Peter A. McCullough, Raymond T. Krediet, H.H. Vincent, Richard A. Ward, Ken Farrington, Rajnish Mehrotra, Peter Kotanko, Francesco Locatelli, Zhi-Hong Liu, Patrick Honoré, Christian Verger, Piet M. Ter Wee, Antonio Santoro, Talat Alp Ikizler, Sergio Stefoni, Markus Ketteler, Guido Bertolini, Daugirdas J.T., A.A. Al-Khader, London Gerard, Alan Maisel, J. Louis Vanherweghem, Vincenzo La Milia, Pasquale Piccinni, V. Marco Ranieri, Heleen M. Oudemans-Van Straaten, Vincenzo Panichi, John R. Prowle, Miguel C. Riella, Marie Schetz, Mark Okusa, Mauro Pittiruti, Mitch Rosner, Jean-Philippe Ryckelynck, Isaac Teitelbaum, Josep Teixido-Planas, Wim Van Biesen, Michael Rocco, Zaccaria Ricci, Bengt Rippe, Andrea Stopper, Dirk G. Struijk, Angela Y. Wang, David Warnock, Michael J Lysaght, Igor M. Sauer, Andrew Shaw, Stanley Shaldon, Mizpah Publishing Service, Druckerei Stückle. Erratum. Blood Purification. 2021; ():1-1.
Chicago/Turabian StyleC. Ronco; Japan Society For Blood Purification In Critical Care (Jsbpcc); Chinese Society Of Blood Purification Administration (Csbpa); Japanese Society For Hemodiafiltration (Js-Hdf); International Society of Blood Purification (ISBP); Peter Stenvinkel; Mei Wang; Akihiro C. Yamashita; Shigeto Oda; Gerhard Lonnemann; Kenichi Matsuda; Stefano Chiaramonte; Nathan W. Levin; Giovambattista Capasso; W.H. Hörl; Kiyoshi Kurokawa; Andrew Davenport; Roger N. Greenwood; Achim Joerres; Michael Haase; Nevin M. Katz; Alexandre Mebazaa; Francesca Martino; Martin K. Kuhlmann; John A. Kellum; Hideki Kawanishi; William F. Keane; Norbert Lameire; Andrew Mooney; Patrick T. Murray; Federico Nalesso; K. Shivanand Nayak; Bruce A. Molitoris; Didier Payen; Miguel Perez Fontan; Beth Marie Piraino; Piotr Ponikowski; Giuseppe Remuzzi; Richard Amerling; Ciro Tetta; Allen R. Nissenson; Madhukar Misra; Victor Gura; Enrico Eugenio Verrina; Stefan H. Jacobson; Stefan D. Anker; Ian C. Baldwin; Mihai Gheorghiade; Massimo Antonelli; Sean M. Bagshaw; Fabio Barbarigo; W. Kline Bolton; Joanne M. Bargman; Joseph V. Bonventre; Edwina A. Brown; John Burkart; David Goldsmith; Jorgen Hegbrant; Stuart L. Goldstein; William L. Henrich; Eric A. Hoste; George L. Bakris; Stefano Bianchi; Jordi Bover; Shigehiko Uchino; Rinaldo Bellomo; P.K.G. Chandran; Lakhmir Chawla; Jorge Cerda; John Collins; Maria Rosa Costanzo; Angel M. de Francisco; Dick de Zeeuw; Oliver Devuyst; Mariano Feriani; Fredric Finkelstein; Salvatore Di Somma; Rosanna Coppo; Ricardo Correa-Rotter; Adrian A. Covic; Mario Cozzolino; Carlo Crepaldi; Franceso Galli; Enrico Fiaccadori; Stephan von Haehling; Daniel Schneditz; Janusz Witowski; Carmine Zoccali; Guido Garosi; Volker Wizemann; Storker Jorstad; Jean-Pierre Wauters; Piergiorgio Messa; Olof Heimburger; Peter A. McCullough; Raymond T. Krediet; H.H. Vincent; Richard A. Ward; Ken Farrington; Rajnish Mehrotra; Peter Kotanko; Francesco Locatelli; Zhi-Hong Liu; Patrick Honoré; Christian Verger; Piet M. Ter Wee; Antonio Santoro; Talat Alp Ikizler; Sergio Stefoni; Markus Ketteler; Guido Bertolini; Daugirdas J.T.; A.A. Al-Khader; London Gerard; Alan Maisel; J. Louis Vanherweghem; Vincenzo La Milia; Pasquale Piccinni; V. Marco Ranieri; Heleen M. Oudemans-Van Straaten; Vincenzo Panichi; John R. Prowle; Miguel C. Riella; Marie Schetz; Mark Okusa; Mauro Pittiruti; Mitch Rosner; Jean-Philippe Ryckelynck; Isaac Teitelbaum; Josep Teixido-Planas; Wim Van Biesen; Michael Rocco; Zaccaria Ricci; Bengt Rippe; Andrea Stopper; Dirk G. Struijk; Angela Y. Wang; David Warnock; Michael J Lysaght; Igor M. Sauer; Andrew Shaw; Stanley Shaldon; Mizpah Publishing Service; Druckerei Stückle. 2021. "Erratum." Blood Purification , no. : 1-1.
Background This study evaluates the effects of active (1α-hydroxylated) vitamin D (AVD) therapy on hypercalcaemia in patients with non-dialysis chronic kidney disease (ND-CKD) and secondary hyperparathyroidism (SHPT). Methods A systematic search of the PubMed, Embase and Cochrane Library databases (up to 14 May 2020) was performed to identify randomized, placebo-controlled trials of single-agent, oral AVD therapies in adults with ND-CKD and SHPT. Only studies with ≥30 participants per arm and ≥6 weeks in duration were eligible. The outcome of interest was the number of subjects with an episode of hypercalcaemia. A meta-analysis of eligible studies was conducted using Comprehensive Meta-Analysis software (version 3.0). Results Six studies (five evaluating paricalcitol, one evaluating alfacalcidol) involving 799 patients were identified. Treatment durations ranged from 16 weeks to 2 years. The weekly doses of paricalcitol administered were 7 (three studies) and 14 µg (two studies); the weekly dose of alfacalcidol was 1.75–7.0 µg. Across all studies, rates of hypercalcaemia were 1.1–43.3% with AVD versus 0–3.4% with placebo. Meta-analysis of the six studies showed that AVD was associated with a 6.6-fold greater probability of hypercalcaemia versus placebo (odds ratio: 6.63, 95% confidence interval: 2.37, 18.55; P < 0.001). Two separate sensitivity analyses (one excluded a study identified as having a high risk of bias; the second excluded two studies that accounted for a large proportion of observed hypercalcaemia events) indicated the primary meta-analysis findings were robust. Conclusions Compared with placebo, AVD significantly increased the risk of hypercalcaemia among ND-CKD patients with SHPT.
Mario Cozzolino; Laurence Bernard; Philipp A Csomor. Active vitamin D increases the risk of hypercalcaemia in non-dialysis chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis. Clinical Kidney Journal 2021, 1 .
AMA StyleMario Cozzolino, Laurence Bernard, Philipp A Csomor. Active vitamin D increases the risk of hypercalcaemia in non-dialysis chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis. Clinical Kidney Journal. 2021; ():1.
Chicago/Turabian StyleMario Cozzolino; Laurence Bernard; Philipp A Csomor. 2021. "Active vitamin D increases the risk of hypercalcaemia in non-dialysis chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis." Clinical Kidney Journal , no. : 1.
Chronic kidney disease (CKD) is characterized by the retention of solutes named uremic toxins, which strongly associate with high morbidity and mortality. Mounting evidence suggests that targeting uremic toxins and/or their pathways may decrease the risk of cardiovascular disease in CKD patients. Dialysis therapies have been developed to improve removal of uremic toxins. Advances in our understanding of uremic retention solutes as well as improvements in dialysis membranes and techniques (HDx, Expanded Hemodialysis) will offer the opportunity to ameliorate clinical symptoms and outcomes, facilitate personalized and targeted dialysis treatment, and improve quality of life, morbidity and mortality.
Paola Ciceri; Mario Cozzolino. Expanded Haemodialysis as a Current Strategy to Remove Uremic Toxins. Toxins 2021, 13, 380 .
AMA StylePaola Ciceri, Mario Cozzolino. Expanded Haemodialysis as a Current Strategy to Remove Uremic Toxins. Toxins. 2021; 13 (6):380.
Chicago/Turabian StylePaola Ciceri; Mario Cozzolino. 2021. "Expanded Haemodialysis as a Current Strategy to Remove Uremic Toxins." Toxins 13, no. 6: 380.
High serum phosphate levels have been associated with increased morbidity and mortality in dialysis patients. Nephrologists routinely counteract the positive phosphate balance in dialysis patients through nutritional counselling, stronger phosphate removal by dialysis and prescription of phosphate binders. An individualized choice of phosphate binders is a desirable option to improve the poor adherence with these medications’ prescription that has been associated with hyperphosphataemia.
Mario Cozzolino; Andrea Galassi; Paola Ciceri. Phosphate binders in dialysis: better satisfied than sorry. Clinical Kidney Journal 2021, 14, 1859 -1860.
AMA StyleMario Cozzolino, Andrea Galassi, Paola Ciceri. Phosphate binders in dialysis: better satisfied than sorry. Clinical Kidney Journal. 2021; 14 (8):1859-1860.
Chicago/Turabian StyleMario Cozzolino; Andrea Galassi; Paola Ciceri. 2021. "Phosphate binders in dialysis: better satisfied than sorry." Clinical Kidney Journal 14, no. 8: 1859-1860.
Background: It is estimated that chronic kidney disease (CKD) accounts globally for 5 to 10 million deaths annually, mainly due to cardiovascular (CV) diseases. Traditional as well as non-traditional CV risk factors such as vascular calcification are believed to drive this disproportionate risk burden. We aimed to investigate the association of coronary artery calcification (CAC) progression with all-cause mortality in patients new to hemodialysis (HD). Methods: Post hoc analysis of the Independent study (NCT00710788). At study inception and after 12 months of follow-up, 414 patients underwent computed tomography imaging for quantification of CAC via the Agatston methods. The square root method was used to assess CAC progression (CACP), and survival analyses were used to test its association with mortality. Results: Over a median follow-up of 36 months, 106 patients died from all causes. Expired patients were older, more likely to be diabetic or to have experienced an atherosclerotic CV event, and exhibited a significantly greater CAC burden (p = 0.002). Survival analyses confirmed an independent association of CAC burden (hazard ratio: 1.29; 95% confidence interval: 1.17–1.44) and CACP (HR: 5.16; 2.61–10.21) with all-cause mortality. CACP mitigated the risk associated with CAC burden (p = 0.002), and adjustment for calcium-free phosphate binder attenuated the strength of the link between CACP and mortality. Conclusions: CAC burden and CACP predict mortality in incident to dialysis patients. However, CACP reduced the risk associated with baseline CAC, and calcium-free phosphate binders attenuated the association of CACP and outcomes, suggesting that CACP modulation may improve survival in this population. Future endeavors are needed to confirm whether drugs or kidney transplantation may attenuate CACP and improve survival in HD patients.
Antonio Bellasi; Luca Di Lullo; Domenico Russo; Roberto Ciarcia; Michele Magnocavallo; Carlo Lavalle; Carlo Ratti; Mario Cozzolino; Biagio Di Iorio. Vascular Calcification Progression Modulates the Risk Associated with Vascular Calcification Burden in Incident to Dialysis Patients. Cells 2021, 10, 1091 .
AMA StyleAntonio Bellasi, Luca Di Lullo, Domenico Russo, Roberto Ciarcia, Michele Magnocavallo, Carlo Lavalle, Carlo Ratti, Mario Cozzolino, Biagio Di Iorio. Vascular Calcification Progression Modulates the Risk Associated with Vascular Calcification Burden in Incident to Dialysis Patients. Cells. 2021; 10 (5):1091.
Chicago/Turabian StyleAntonio Bellasi; Luca Di Lullo; Domenico Russo; Roberto Ciarcia; Michele Magnocavallo; Carlo Lavalle; Carlo Ratti; Mario Cozzolino; Biagio Di Iorio. 2021. "Vascular Calcification Progression Modulates the Risk Associated with Vascular Calcification Burden in Incident to Dialysis Patients." Cells 10, no. 5: 1091.
Cardiovascular disease is a frequent complication and the most common cause of death in patients with CKD. Despite landmark medical advancements, mortality due to cardiovascular disease is still 20 times higher in CKD patients than in the general population, which is mainly due to the high prevalence of risk factors in this group. Indeed, in addition to traditional cardiovascular risk factors, CKD patients are exposed to nontraditional ones, which include metabolic, hormonal, and inflammatory alterations. The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has brought novel challenges for both cardiologists and nephrologists alike. Emerging evidence indicates that coronavirus disease 2019 (COVID-19) increases the risk of cardiovascular events and that several aspects of the disease may synergize with pre-existing cardiovascular risk factors in CKD patients. A better understanding of these mechanisms is pivotal for the prevention and treatment of cardiovascular events in this context, and we believe that additional clinical and experimental studies are needed to improve cardiovascular outcomes in CKD patients with COVID-19. In this review, we provide a summary of traditional and nontraditional cardiovascular risk factors in CKD patients, discussing their interaction with SARS-CoV-2 infection and focusing on COVID-19-related cardiovascular complications that may severely affect short- and long-term outcomes in this high-risk population.
Manuel Alfredo Podestà; Federica Valli; Andrea Galassi; Matthias A. Cassia; Paola Ciceri; Lucia Barbieri; Stefano Carugo; Mario Cozzolino. COVID-19 in Chronic Kidney Disease: The Impact of Old and Novel Cardiovascular Risk Factors. Blood Purification 2021, 1 -10.
AMA StyleManuel Alfredo Podestà, Federica Valli, Andrea Galassi, Matthias A. Cassia, Paola Ciceri, Lucia Barbieri, Stefano Carugo, Mario Cozzolino. COVID-19 in Chronic Kidney Disease: The Impact of Old and Novel Cardiovascular Risk Factors. Blood Purification. 2021; ():1-10.
Chicago/Turabian StyleManuel Alfredo Podestà; Federica Valli; Andrea Galassi; Matthias A. Cassia; Paola Ciceri; Lucia Barbieri; Stefano Carugo; Mario Cozzolino. 2021. "COVID-19 in Chronic Kidney Disease: The Impact of Old and Novel Cardiovascular Risk Factors." Blood Purification , no. : 1-10.
The impressive estimated number of chronic kidney disease (CKD) patients in the world justifies any possible effort at implementing preventive measures of disease progression. Renal insufficiency is associated with significant changes in the electrolyte handling and body balance of sodium, potassium, phosphate, magnesium, and calcium, all of which are biologically vital molecules. Dietary habits could contribute significantly to the optimal management of possible derangements. In this review, we examined the available evidence recommending dietary prescriptions for these five elements aiming at reducing CKD progression. Clear evidence that specific dietary prescriptions may halt or reduce CKD progression is lacking. However, some practical recommendations are possible to prescribe the best possible therapy to the individual CKD patient.
Sandro Mazzaferro; Natalia de Martini; Jorge Cannata-Andía; Mario Cozzolino; Piergiorgio Messa; Silverio Rotondi; Lida Tartaglione; Marzia Pasquali; on behalf of the ERA-EDTA CKD-MBD Working Group. Focus on the Possible Role of Dietary Sodium, Potassium, Phosphate, Magnesium, and Calcium on CKD Progression. Journal of Clinical Medicine 2021, 10, 958 .
AMA StyleSandro Mazzaferro, Natalia de Martini, Jorge Cannata-Andía, Mario Cozzolino, Piergiorgio Messa, Silverio Rotondi, Lida Tartaglione, Marzia Pasquali, on behalf of the ERA-EDTA CKD-MBD Working Group. Focus on the Possible Role of Dietary Sodium, Potassium, Phosphate, Magnesium, and Calcium on CKD Progression. Journal of Clinical Medicine. 2021; 10 (5):958.
Chicago/Turabian StyleSandro Mazzaferro; Natalia de Martini; Jorge Cannata-Andía; Mario Cozzolino; Piergiorgio Messa; Silverio Rotondi; Lida Tartaglione; Marzia Pasquali; on behalf of the ERA-EDTA CKD-MBD Working Group. 2021. "Focus on the Possible Role of Dietary Sodium, Potassium, Phosphate, Magnesium, and Calcium on CKD Progression." Journal of Clinical Medicine 10, no. 5: 958.
Vascular and valvular calcifications are highly prevalent in kidney transplant recipients (KTRs) and are associated with an increased risk of cardiovascular events, which represent the leading cause of long-term mortality in these patients. However, cardiovascular calcification has been traditionally considered as a condition mostly associated with advanced chronic kidney disease stages and dialysis, and comparatively fewer studies have assessed its impact after kidney transplantation. Despite partial or complete resolution of uraemia-associated metabolic derangements, KTRs are still exposed to several pro-calcifying stimuli that favour the progression of pre-existing vascular calcifications or their de novo development. Traditional risk factors, bone mineral disorders, inflammation, immunosuppressive drugs and deficiency of calcification inhibitors may all play a role, and strategies to correct or minimize their effects are urgently needed. The aim of this work is to provide an overview of established and putative mediators involved in the pathogenesis of cardiovascular calcification in kidney transplantation, and to describe the clinical and radiological features of these forms. We also discuss current evidence on preventive strategies to delay the progression of cardiovascular calcifications in KTRs, as well as novel therapeutic candidates to potentially prevent their long-term deleterious effects.
Manuel Alfredo Podestà; David Cucchiari; Paola Ciceri; Piergiorgio Messa; José-Vicente Torregrosa; Mario Cozzolino. Cardiovascular calcifications in kidney transplant recipients. Nephrology Dialysis Transplantation 2021, 1 .
AMA StyleManuel Alfredo Podestà, David Cucchiari, Paola Ciceri, Piergiorgio Messa, José-Vicente Torregrosa, Mario Cozzolino. Cardiovascular calcifications in kidney transplant recipients. Nephrology Dialysis Transplantation. 2021; ():1.
Chicago/Turabian StyleManuel Alfredo Podestà; David Cucchiari; Paola Ciceri; Piergiorgio Messa; José-Vicente Torregrosa; Mario Cozzolino. 2021. "Cardiovascular calcifications in kidney transplant recipients." Nephrology Dialysis Transplantation , no. : 1.
Andrea Galassi; Lorenza Magagnoli; Mario Cozzolino. COVID-19 in a dialysis center in Milan from March to June 2020: understanding how to respond to the second wave of the pandemic. Journal of Nephrology 2021, 34, 11 -14.
AMA StyleAndrea Galassi, Lorenza Magagnoli, Mario Cozzolino. COVID-19 in a dialysis center in Milan from March to June 2020: understanding how to respond to the second wave of the pandemic. Journal of Nephrology. 2021; 34 (1):11-14.
Chicago/Turabian StyleAndrea Galassi; Lorenza Magagnoli; Mario Cozzolino. 2021. "COVID-19 in a dialysis center in Milan from March to June 2020: understanding how to respond to the second wave of the pandemic." Journal of Nephrology 34, no. 1: 11-14.
The novel coronavirus, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a pandemic in March 2020 by the World Health Organization. Older individuals and patients with comorbid conditions such as hypertension, heart disease, diabetes, lung disease, chronic kidney disease (CKD) and immunologic diseases are at higher risk of contracting this severe infection. In particular, patients with advanced CKD constitute a vulnerable population and a challenge in the prevention and control of the disease. Home-based renal replacement therapies offer an opportunity to manage patients remotely, thus reducing the likelihood of infection due to direct human interaction. Patients are seen less frequently, limiting the close interaction between patients and healthcare workers who may contract and spread the disease. However, while home dialysis is a reasonable choice at this time due to the advantage of isolation of patients, measures must be assured to implement the program. Despite its logistical benefits, outpatient haemodialysis also presents certain challenges during times of crises such as the coronavirus disease 2019 (COVID-19) pandemic and potentially future ones.
Mario Cozzolino; Ferruccio Conte; Fulvia Zappulo; Paola Ciceri; Andrea Galassi; Irene Capelli; Giacomo Magnoni; Gaetano La Manna. COVID-19 pandemic era: is it time to promote home dialysis and peritoneal dialysis? Clinical Kidney Journal 2021, 14, i6 -i13.
AMA StyleMario Cozzolino, Ferruccio Conte, Fulvia Zappulo, Paola Ciceri, Andrea Galassi, Irene Capelli, Giacomo Magnoni, Gaetano La Manna. COVID-19 pandemic era: is it time to promote home dialysis and peritoneal dialysis? Clinical Kidney Journal. 2021; 14 (Supplement):i6-i13.
Chicago/Turabian StyleMario Cozzolino; Ferruccio Conte; Fulvia Zappulo; Paola Ciceri; Andrea Galassi; Irene Capelli; Giacomo Magnoni; Gaetano La Manna. 2021. "COVID-19 pandemic era: is it time to promote home dialysis and peritoneal dialysis?" Clinical Kidney Journal 14, no. Supplement: i6-i13.
Background: Vascular calcification (VC) is a marker of cardiovascular (CV) disease and various methods allow for presence and extension assessment in different arterial districts. Nevertheless, it is currently unclear which one of these methods for VC evaluation best predict outcome and if this piece of information adds to the predictive value of traditional CV risk factors in patients receiving hemodialysis (HD). Methods: data of 184 of the 466 patients followed in the Independent study (NCT00710788) were post hoc examined to assess the association three concurrent measures of vascular calcification and all-cause survival. Specifically, coronary artery calcification (CAC) was determined by the Agatston and the volume score while abdominal aorta calcification was determined by plain X-ray of the lumbar spine (Kauppila score (KS)). Survival and regression models as well as metrics of risk recalculation were used to test the association of VC and outcome beyond the Framingham risk score. Results: Middle-age (62.6(15.8) years) men (51%) and women (49%) starting HD were analyzed. Over 36 (median 36; interquartile range: 8–36) months of follow-up 69 patients expired. Each measure of VC (CAC or KS) predicted all-cause mortality independently factors commonly associated with all-cause survival (p < 0.001). Far more importantly, each measurement of VC significantly improved risk prediction and patient reclassification (p < 0.001) beyond traditional cardiovascular risk factors. Conclusions: Overall, presence and extension of VC, irrespective of the arterial site, predict risk of all-cause of death in patients starting hemodialysis. Of note, both CAC and KS increase risk stratification beyond traditional CV risk factors. However, future efforts are needed to assess whether a risk-based approach encompassing VC screening to guide HD patient management improves survival.
Antonio Bellasi; Luca Di Lullo; Domenico Russo; Roberto Ciarcia; Michele Magnocavallo; Carlo Lavalle; Carlo Ratti; Maria Fusaro; Mario Cozzolino; Biagio Di Iorio. Predictive Value of Measures of Vascular Calcification Burden and Progression for Risk of Death in Incident to Dialysis Patients. Journal of Clinical Medicine 2021, 10, 376 .
AMA StyleAntonio Bellasi, Luca Di Lullo, Domenico Russo, Roberto Ciarcia, Michele Magnocavallo, Carlo Lavalle, Carlo Ratti, Maria Fusaro, Mario Cozzolino, Biagio Di Iorio. Predictive Value of Measures of Vascular Calcification Burden and Progression for Risk of Death in Incident to Dialysis Patients. Journal of Clinical Medicine. 2021; 10 (3):376.
Chicago/Turabian StyleAntonio Bellasi; Luca Di Lullo; Domenico Russo; Roberto Ciarcia; Michele Magnocavallo; Carlo Lavalle; Carlo Ratti; Maria Fusaro; Mario Cozzolino; Biagio Di Iorio. 2021. "Predictive Value of Measures of Vascular Calcification Burden and Progression for Risk of Death in Incident to Dialysis Patients." Journal of Clinical Medicine 10, no. 3: 376.
Mario Cozzolino; Paola Ciceri. Transforming the frail and elderly patient into an Iron Man: how to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease. Journal of Nephrology 2021, 34, 1049 -1051.
AMA StyleMario Cozzolino, Paola Ciceri. Transforming the frail and elderly patient into an Iron Man: how to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease. Journal of Nephrology. 2021; 34 (4):1049-1051.
Chicago/Turabian StyleMario Cozzolino; Paola Ciceri. 2021. "Transforming the frail and elderly patient into an Iron Man: how to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease." Journal of Nephrology 34, no. 4: 1049-1051.
Native kidneys have several functions: maintain haemodynamic balance, blood pressure, electrolyte and solute concentration; excrete metabolites and liver-conjugated molecules; produce active vitamin D; and secrete erythropoietin. According to K/DOQI and KDIGO consensus guidelines, CKD is defined as a heterogeneous group of disorders characterized by alterations in kidney structure and function, which manifest in various ways depending upon the underlying causes and the severity of disease. All of these disorders follow a progressive course and eventually lead to such a decrement in kidney function that renal replacement therapy has to be instituted. Patients with advanced CKD represent a heavy burden for the national health systems not only in terms of their diseases per se but also, and especially, because of the high rate of comorbidities and the increased risk of mortality, particularly for cardiovascular complications [1].
Mario Cozzolino; Claudio Ronco. Medium Cut-Off Membranes: Incremental or Quantum Leap Innovation in Haemodialysis? Blood Purification 2020, 1 -4.
AMA StyleMario Cozzolino, Claudio Ronco. Medium Cut-Off Membranes: Incremental or Quantum Leap Innovation in Haemodialysis? Blood Purification. 2020; ():1-4.
Chicago/Turabian StyleMario Cozzolino; Claudio Ronco. 2020. "Medium Cut-Off Membranes: Incremental or Quantum Leap Innovation in Haemodialysis?" Blood Purification , no. : 1-4.
Chronic kidney disease (CKD) is a major health problem because of its high prevalence, associated complications and high treatment costs. Several aspects of CKD differ significantly in the Eastern European nephrology community compared with Western Europe because of different geographic, socio-economic, infrastructure, cultural and educational features. The two most frequent aetiologies of CKD, DM and hypertension, and many other predisposing factors, are more frequent in the Eastern region, resulting in more prevalent CKD Stages 3–5. Interventions may minimize the potential drawbacks of the high prevalence of CKD in Eastern Europe, which include several options at various stages of the disease, such as raising public, medical personnel and healthcare authorities awareness; early detection by screening high-risk populations; preventing progression and CKD-related complications by training health professionals and patients; promoting transplantation or home dialysis as the preferred modality; disseminating and implementing guidelines and guided therapy and encouraging/supporting country-specific observational research as well as international collaborative projects. Specific ways to significantly impact CKD-related problems in every region of Europe through education, science and networking are collaboration with non-nephrology European societies who have a common interest in CKD and its associated complications, representation through an advisory role within nephrology via national nephrology societies, contributing to the training of local nephrologists and stimulating patient-oriented research. The latter is mandatory to identify country-specific kidney disease–related priorities. Active involvement of patients in this research via collaboration with the European Kidney Patient Federation or national patient federations is imperative to ensure that projects reflect specific patient needs.
Mehmet Şükrü Sever; Kitty J Jager; Raymond Vanholder; Benedicte Stengel; Jerome Harambat; Patrik Finne; Vladimir Tesař; Myftar Barbullushi; Inga A Bumblytė; Elena Zakharova; Goce Spasovski; Halima Resic; Andrzej Wiecek; Peter J Blankestijn; Annette Bruchfeld; Mario Cozzolino; Dimitris Goumenos; Maria Jose Soler; Ivan Rychlík; Kate I Stevens; Christoph Wanner; Carmine Zoccali; Ziad A Massy. A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community. Clinical Kidney Journal 2020, 14, 23 -35.
AMA StyleMehmet Şükrü Sever, Kitty J Jager, Raymond Vanholder, Benedicte Stengel, Jerome Harambat, Patrik Finne, Vladimir Tesař, Myftar Barbullushi, Inga A Bumblytė, Elena Zakharova, Goce Spasovski, Halima Resic, Andrzej Wiecek, Peter J Blankestijn, Annette Bruchfeld, Mario Cozzolino, Dimitris Goumenos, Maria Jose Soler, Ivan Rychlík, Kate I Stevens, Christoph Wanner, Carmine Zoccali, Ziad A Massy. A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community. Clinical Kidney Journal. 2020; 14 (1):23-35.
Chicago/Turabian StyleMehmet Şükrü Sever; Kitty J Jager; Raymond Vanholder; Benedicte Stengel; Jerome Harambat; Patrik Finne; Vladimir Tesař; Myftar Barbullushi; Inga A Bumblytė; Elena Zakharova; Goce Spasovski; Halima Resic; Andrzej Wiecek; Peter J Blankestijn; Annette Bruchfeld; Mario Cozzolino; Dimitris Goumenos; Maria Jose Soler; Ivan Rychlík; Kate I Stevens; Christoph Wanner; Carmine Zoccali; Ziad A Massy. 2020. "A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community." Clinical Kidney Journal 14, no. 1: 23-35.
Diabetes, hypertension and cardiovascular disease have been listed as risk factors for severe coronavirus disease 2019 (COVID-19) since the first report of the disease in January 2020. However, this report did not mention chronic kidney disease (CKD) nor did it provide information on the relevance of estimated glomerular filtration rate (eGFR) or albuminuria. As the disease spread across the globe, information on larger populations with greater granularity on risk factors emerged. The recently published OpenSAFELY project analysed factors associated with COVID-19 death in 17 million patients. The picture that arose differs significantly from initial reports. For example, hypertension is not an independent risk factor for COVID-19 death [adjusted hazard ratio (aHR) 0.89], but renal disease very much is. Dialysis (aHR 3.69), organ transplantation (aHR 3.53) and CKD (aHR 2.52 for patients with eGFR <30 mL/min/1.73 m2) represent three of the four comorbidities associated with the highest mortality risk from COVID-19. The risk associated with CKD Stages 4 and 5 is higher than the risk associated with diabetes mellitus (aHR range 1.31–1.95, depending upon glycaemic control) or chronic heart disease (aHR 1.17). In another recent publication, the Global Burden of Disease collaboration identified that worldwide, CKD is the most prevalent risk factor for severe COVID-19. Moreover, the distribution of risk factors for COVID-19 mortality appears to be different in patients with CKD when compared with the general population. The high prevalence of CKD in combination with the elevated risk of mortality from COVID-19 in CKD necessitates urgent action for this group of patients. This article defines essential action points (summarized in Box 1), among which is advocating the inclusion of CKD patients in clinical trials testing the efficacy of drugs and vaccines to prevent severe COVID-19.
Era-Edta Council; Alberto Ortiz; Mario Cozzolino; Danilo Fliser; Denis Fouque; Dimitrios Goumenos; Ziad A Massy; Alexander R Rosenkranz; Ivan Rychlık; Maria Jose Soler; Kate Stevens; Roser Torra; Serhan Tuglular; Christoph Wanner; Ron T Gansevoort; Raphaël Duivenvoorden; Casper F M Franssen; Marc H Hemmelder; Luuk B Hilbrands; Kitty J Jager; Marlies Noordzij; Priya Vart; ERACODA Working Group. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrology Dialysis Transplantation 2020, 36, 87 -94.
AMA StyleEra-Edta Council, Alberto Ortiz, Mario Cozzolino, Danilo Fliser, Denis Fouque, Dimitrios Goumenos, Ziad A Massy, Alexander R Rosenkranz, Ivan Rychlık, Maria Jose Soler, Kate Stevens, Roser Torra, Serhan Tuglular, Christoph Wanner, Ron T Gansevoort, Raphaël Duivenvoorden, Casper F M Franssen, Marc H Hemmelder, Luuk B Hilbrands, Kitty J Jager, Marlies Noordzij, Priya Vart, ERACODA Working Group. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrology Dialysis Transplantation. 2020; 36 (1):87-94.
Chicago/Turabian StyleEra-Edta Council; Alberto Ortiz; Mario Cozzolino; Danilo Fliser; Denis Fouque; Dimitrios Goumenos; Ziad A Massy; Alexander R Rosenkranz; Ivan Rychlık; Maria Jose Soler; Kate Stevens; Roser Torra; Serhan Tuglular; Christoph Wanner; Ron T Gansevoort; Raphaël Duivenvoorden; Casper F M Franssen; Marc H Hemmelder; Luuk B Hilbrands; Kitty J Jager; Marlies Noordzij; Priya Vart; ERACODA Working Group. 2020. "Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA." Nephrology Dialysis Transplantation 36, no. 1: 87-94.
Patients affected by chronic kidney disease (CKD) have a greater risk of mortality than the general population. Fatal cardiovascular events are the most frequent cause of death in CKD patients, especially in the late stages of disease. Derangement of mineral metabolism and hyperphosphataemia are currently accepted as pivotal triggers of these vascular complications. Phosphate binders represent the common strategy to counteract hyperphosphataemia in dialysis patients. Several studies have reported a reduction in mortality risk in dialysis patients receiving phosphate binders compared with untreated patients, independent of the class of binder prescribed.
Mario Cozzolino; Andrea Galassi; Paola Ciceri. Do we need new phosphate binders in dialysis? Clinical Kidney Journal 2020, 14, 474 -475.
AMA StyleMario Cozzolino, Andrea Galassi, Paola Ciceri. Do we need new phosphate binders in dialysis? Clinical Kidney Journal. 2020; 14 (2):474-475.
Chicago/Turabian StyleMario Cozzolino; Andrea Galassi; Paola Ciceri. 2020. "Do we need new phosphate binders in dialysis?" Clinical Kidney Journal 14, no. 2: 474-475.
The most accurate way of assessing kidney function is the measurement of the glomerular filtration rate (GFR). Since, we do not have good formulae to estimate GFR in elderly, in this study we evaluate the accuracy of the most commonly used formulas for the estimation of GFR in comparison with direct measurement in elderly. 85 patients (51 males and 34 females), with an average age of 76.2 ± 4.4 years, 42% already diagnosed with chronic kidney disease (CKD) were investigated. Two plasma samples were collected between 60-90 and 165-195 minutes after injection of 99mTc-DTPA, and the GFR was calculated applying Charles D. Russell’s two-sample method. When comparing the GFR values obtained from the various formulae by creatinine levels with the GFR values obtained by measuring 99mTc-DTPA residue, the following concordance values emerged: (1) MDRD: 57.5 ± 9.59 %; (2) Cockroft-Gault: 48.33 ± 24.93; (3) CKD-EPI: 49.40 ± 26.30; (4) BIS1: 58 ± 6.79. Our data shows a greater concordance between the GFR values calculated with the Russell’s method and the estimated values of GFR when the latter are calculated using the MDRD or BIS1 formulae. (www.actabiomedica.it)
Maioli Claudio; Mangano Michela; Conte Ferruccio; Del Sole Angelo; Tagliabue Luca; Alberici Federico; Galassi Andrea; Cozzolino Mario. The ideal marker for measuring GFR: what are we looking for? 2020, 91, e2020132 .
AMA StyleMaioli Claudio, Mangano Michela, Conte Ferruccio, Del Sole Angelo, Tagliabue Luca, Alberici Federico, Galassi Andrea, Cozzolino Mario. The ideal marker for measuring GFR: what are we looking for? . 2020; 91 (4):e2020132.
Chicago/Turabian StyleMaioli Claudio; Mangano Michela; Conte Ferruccio; Del Sole Angelo; Tagliabue Luca; Alberici Federico; Galassi Andrea; Cozzolino Mario. 2020. "The ideal marker for measuring GFR: what are we looking for?" 91, no. 4: e2020132.
In the article by Theodorakopoulou et al. entitled “The Effects of Nebivolol and Irbesartan on Ambulatory Aortic Blood Pressure and Arterial Stiffness in Hemodialysis Patients with Intradialytic Hypertension” [Blood Purif., DOI: 10.1159/000507913] point b on page 3 should read as follows:
C. Ronco; Japan Society For Blood Purification In Critical Care (Jsbpcc); Chinese Society Of Blood Purification Administration (Csbpa); Japanese Society For Hemodiafiltration (Js-Hdf); International Society of Blood Purification (ISBP); Peter Stenvinkel; Mei Wang; Akihiro C. Yamashita; Shigeto Oda; Gerhard Lonnemann; Kenichi Matsuda; Stefano Chiaramonte; Nathan W. Levin; Giovambattista Capasso; W.H. Hörl; Kiyoshi Kurokawa; Andrew Davenport; Roger N. Greenwood; Achim Joerres; Michael Haase; Nevin M. Katz; Alexandre Mebazaa; Francesca Martino; Martin K. Kuhlmann; John A. Kellum; Hideki Kawanishi; William F. Keane; Norbert Lameire; Andrew Mooney; Patrick T. Murray; Federico Nalesso; K. Shivanand Nayak; Bruce A. Molitoris; Didier Payen; Miguel Perez Fontan; Beth Marie Piraino; Piotr Ponikowski; Giuseppe Remuzzi; Richard Amerling; Ciro Tetta; Allen R. Nissenson; Madhukar Misra; Victor Gura; Enrico Eugenio Verrina; Stefan H. Jacobson; Stefan D. Anker; Ian C. Baldwin; Mihai Gheorghiade; Massimo Antonelli; Sean M. Bagshaw; Fabio Barbarigo; W. Kline Bolton; Joanne M. Bargman; Joseph V. Bonventre; Edwina A. Brown; John Burkart; David Goldsmith; Jorgen Hegbrant; Stuart L. Goldstein; William L. Henrich; Eric A. Hoste; George L. Bakris; Stefano Bianchi; Jordi Bover; Shigehiko Uchino; Rinaldo Bellomo; P.K.G. Chandran; Lakhmir Chawla; Jorge Cerda; John Collins; Maria Rosa Costanzo; Angel M. De Francisco; Dick De Zeeuw; Oliver Devuyst; Mariano Feriani; Fredric Finkelstein; Salvatore Di Somma; Rosanna Coppo; Ricardo Correa-Rotter; Adrian A. Covic; Mario Cozzolino; Carlo Crepaldi; Franceso Galli; Enrico Fiaccadori; Stephan Von Haehling; Daniel Schneditz; Janusz Witowski; Carmine Zoccali; Guido Garosi; Volker Wizemann; Storker Jorstad; Jean-Pierre Wauters; Piergiorgio Messa; Olof Heimburger; Peter A. McCullough; Raymond T. Krediet; H.H. Vincent; Richard A. Ward; Ken Farrington; Rajnish Mehrotra; Peter Kotanko; Francesco Locatelli; Zhi-Hong Liu; Patrick Honoré; Christian Verger; Piet M. Ter Wee; Antonio Santoro; Talat Alp Ikizler; Sergio Stefoni; Markus Ketteler; Guido Bertolini; Daugirdas J.T.; A.A. Al-Khader; London Gerard; Alan Maisel; J. Louis Vanherweghem; Vincenzo La Milia; Pasquale Piccinni; V. Marco Ranieri; Heleen M. Oudemans-Van Straaten; Vincenzo Panichi; John R. Prowle; Miguel C. Riella; Marie Schetz; Mark Okusa; Mauro Pittiruti; Mitch Rosner; Jean-Philippe Ryckelynck; Isaac Teitelbaum; Josep Teixido-Planas; Wim Van Biesen; Michael Rocco; Zaccaria Ricci; Bengt Rippe; Andrea Stopper; Dirk G. Struijk; Angela Y. Wang; David Warnock; Michael J Lysaght; Igor M. Sauer; Andrew Shaw; Stanley Shaldon; Mizpah Publishing Service; Druckerei Stückle. Erratum. Blood Purification 2020, 1 -1.
AMA StyleC. Ronco, Japan Society For Blood Purification In Critical Care (Jsbpcc), Chinese Society Of Blood Purification Administration (Csbpa), Japanese Society For Hemodiafiltration (Js-Hdf), International Society of Blood Purification (ISBP), Peter Stenvinkel, Mei Wang, Akihiro C. Yamashita, Shigeto Oda, Gerhard Lonnemann, Kenichi Matsuda, Stefano Chiaramonte, Nathan W. Levin, Giovambattista Capasso, W.H. Hörl, Kiyoshi Kurokawa, Andrew Davenport, Roger N. Greenwood, Achim Joerres, Michael Haase, Nevin M. Katz, Alexandre Mebazaa, Francesca Martino, Martin K. Kuhlmann, John A. Kellum, Hideki Kawanishi, William F. Keane, Norbert Lameire, Andrew Mooney, Patrick T. Murray, Federico Nalesso, K. Shivanand Nayak, Bruce A. Molitoris, Didier Payen, Miguel Perez Fontan, Beth Marie Piraino, Piotr Ponikowski, Giuseppe Remuzzi, Richard Amerling, Ciro Tetta, Allen R. Nissenson, Madhukar Misra, Victor Gura, Enrico Eugenio Verrina, Stefan H. Jacobson, Stefan D. Anker, Ian C. Baldwin, Mihai Gheorghiade, Massimo Antonelli, Sean M. Bagshaw, Fabio Barbarigo, W. Kline Bolton, Joanne M. Bargman, Joseph V. Bonventre, Edwina A. Brown, John Burkart, David Goldsmith, Jorgen Hegbrant, Stuart L. Goldstein, William L. Henrich, Eric A. Hoste, George L. Bakris, Stefano Bianchi, Jordi Bover, Shigehiko Uchino, Rinaldo Bellomo, P.K.G. Chandran, Lakhmir Chawla, Jorge Cerda, John Collins, Maria Rosa Costanzo, Angel M. De Francisco, Dick De Zeeuw, Oliver Devuyst, Mariano Feriani, Fredric Finkelstein, Salvatore Di Somma, Rosanna Coppo, Ricardo Correa-Rotter, Adrian A. Covic, Mario Cozzolino, Carlo Crepaldi, Franceso Galli, Enrico Fiaccadori, Stephan Von Haehling, Daniel Schneditz, Janusz Witowski, Carmine Zoccali, Guido Garosi, Volker Wizemann, Storker Jorstad, Jean-Pierre Wauters, Piergiorgio Messa, Olof Heimburger, Peter A. McCullough, Raymond T. Krediet, H.H. Vincent, Richard A. Ward, Ken Farrington, Rajnish Mehrotra, Peter Kotanko, Francesco Locatelli, Zhi-Hong Liu, Patrick Honoré, Christian Verger, Piet M. Ter Wee, Antonio Santoro, Talat Alp Ikizler, Sergio Stefoni, Markus Ketteler, Guido Bertolini, Daugirdas J.T., A.A. Al-Khader, London Gerard, Alan Maisel, J. Louis Vanherweghem, Vincenzo La Milia, Pasquale Piccinni, V. Marco Ranieri, Heleen M. Oudemans-Van Straaten, Vincenzo Panichi, John R. Prowle, Miguel C. Riella, Marie Schetz, Mark Okusa, Mauro Pittiruti, Mitch Rosner, Jean-Philippe Ryckelynck, Isaac Teitelbaum, Josep Teixido-Planas, Wim Van Biesen, Michael Rocco, Zaccaria Ricci, Bengt Rippe, Andrea Stopper, Dirk G. Struijk, Angela Y. Wang, David Warnock, Michael J Lysaght, Igor M. Sauer, Andrew Shaw, Stanley Shaldon, Mizpah Publishing Service, Druckerei Stückle. Erratum. Blood Purification. 2020; ():1-1.
Chicago/Turabian StyleC. Ronco; Japan Society For Blood Purification In Critical Care (Jsbpcc); Chinese Society Of Blood Purification Administration (Csbpa); Japanese Society For Hemodiafiltration (Js-Hdf); International Society of Blood Purification (ISBP); Peter Stenvinkel; Mei Wang; Akihiro C. Yamashita; Shigeto Oda; Gerhard Lonnemann; Kenichi Matsuda; Stefano Chiaramonte; Nathan W. Levin; Giovambattista Capasso; W.H. Hörl; Kiyoshi Kurokawa; Andrew Davenport; Roger N. Greenwood; Achim Joerres; Michael Haase; Nevin M. Katz; Alexandre Mebazaa; Francesca Martino; Martin K. Kuhlmann; John A. Kellum; Hideki Kawanishi; William F. Keane; Norbert Lameire; Andrew Mooney; Patrick T. Murray; Federico Nalesso; K. Shivanand Nayak; Bruce A. Molitoris; Didier Payen; Miguel Perez Fontan; Beth Marie Piraino; Piotr Ponikowski; Giuseppe Remuzzi; Richard Amerling; Ciro Tetta; Allen R. Nissenson; Madhukar Misra; Victor Gura; Enrico Eugenio Verrina; Stefan H. Jacobson; Stefan D. Anker; Ian C. Baldwin; Mihai Gheorghiade; Massimo Antonelli; Sean M. Bagshaw; Fabio Barbarigo; W. Kline Bolton; Joanne M. Bargman; Joseph V. Bonventre; Edwina A. Brown; John Burkart; David Goldsmith; Jorgen Hegbrant; Stuart L. Goldstein; William L. Henrich; Eric A. Hoste; George L. Bakris; Stefano Bianchi; Jordi Bover; Shigehiko Uchino; Rinaldo Bellomo; P.K.G. Chandran; Lakhmir Chawla; Jorge Cerda; John Collins; Maria Rosa Costanzo; Angel M. De Francisco; Dick De Zeeuw; Oliver Devuyst; Mariano Feriani; Fredric Finkelstein; Salvatore Di Somma; Rosanna Coppo; Ricardo Correa-Rotter; Adrian A. Covic; Mario Cozzolino; Carlo Crepaldi; Franceso Galli; Enrico Fiaccadori; Stephan Von Haehling; Daniel Schneditz; Janusz Witowski; Carmine Zoccali; Guido Garosi; Volker Wizemann; Storker Jorstad; Jean-Pierre Wauters; Piergiorgio Messa; Olof Heimburger; Peter A. McCullough; Raymond T. Krediet; H.H. Vincent; Richard A. Ward; Ken Farrington; Rajnish Mehrotra; Peter Kotanko; Francesco Locatelli; Zhi-Hong Liu; Patrick Honoré; Christian Verger; Piet M. Ter Wee; Antonio Santoro; Talat Alp Ikizler; Sergio Stefoni; Markus Ketteler; Guido Bertolini; Daugirdas J.T.; A.A. Al-Khader; London Gerard; Alan Maisel; J. Louis Vanherweghem; Vincenzo La Milia; Pasquale Piccinni; V. Marco Ranieri; Heleen M. Oudemans-Van Straaten; Vincenzo Panichi; John R. Prowle; Miguel C. Riella; Marie Schetz; Mark Okusa; Mauro Pittiruti; Mitch Rosner; Jean-Philippe Ryckelynck; Isaac Teitelbaum; Josep Teixido-Planas; Wim Van Biesen; Michael Rocco; Zaccaria Ricci; Bengt Rippe; Andrea Stopper; Dirk G. Struijk; Angela Y. Wang; David Warnock; Michael J Lysaght; Igor M. Sauer; Andrew Shaw; Stanley Shaldon; Mizpah Publishing Service; Druckerei Stückle. 2020. "Erratum." Blood Purification , no. : 1-1.